Glenmark Pharma: Plans To Achieve 70% Branded Products By 2030 While Focusing On Innovative Medications. 💊📈

 19 Jul 2025 01:29 PM

Glenmark Pharma: Plans To Achieve 70% Branded Products By 2030 While Focusing On Innovative Medications. 💊📈

Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay

 18 Jul 2025 10:06 AM

Sudip Bandyopadhyay of Inditrade Capital discusses the positive outlook for the Indian pharma sector following the easing of tariff concerns. He highlights Sun Pharma's promising developments and Glenmark's landmark R&D deal. Bandyopadhyay also notes the expected price hike in the steel industry due to increased global demand, while emphasizing company-specific uncertainties like JSW Steel's Bhushan Steel strategy.

Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P

 17 Jul 2025 08:14 PM

S&P Global Ratings projects Glenmark Pharmaceuticals will achieve a net cash positive position following its licensing agreement with AbbVie Inc. This deal, concerning ISB 2001, is expected to significantly strengthen Glenmark's financial standing and liquidity, reversing a previous net debt.

Glenmark Pharma: S&P States Co's Licensing Agreement Will Make It Net Cash Positive 💰🚀

 17 Jul 2025 05:08 PM

Glenmark Pharma: S&P States Co's Licensing Agreement Will Make It Net Cash Positive 💰🚀

Avoid pure play brokerage firms, go for wealth management stocks: Hemang Jani

 17 Jul 2025 12:50 PM

Hemang Jani suggests caution towards pure-play brokerage firms due to their F&O volume reliance, favoring wealth management companies like Nuvama and HDFC AMC. SBI's QIP is viewed positively, while Tech Mahindra's results were mixed, with communication segment showing promise. Glenmark's recent surge makes it less attractive currently, but Aurobindo Pharma and Lupin are favored in the pharma sector.

Glenmark Pharmaceuticals targets 70% branded portfolio by 2030, boosts focus on novel drugs

 17 Jul 2025 12:45 AM

Glenmark Pharmaceuticals is transitioning into an innovation-driven company over the next 4-5 years, emphasizing its novel drug portfolio and strengthening its branded business. By 2030, the company aims for 70% of its revenue to come from branded products, focusing on dermatology, respiratory, and oncology. A recent deal with AbbVie for its cancer drug ISB 2001 highlights this strategic shift.

Glenmark Pharma: Aims To Become A Leading Global Pharmaceutical Company By Expanding Its Branded And Specialty Products, Unlocking Biotech Potential Through IGI, And Focusing On Sustainable Growth In Key Therapeutic Areas And Regions. 💊🌍

 16 Jul 2025 08:40 PM

Glenmark Pharma: Aims To Become A Leading Global Pharmaceutical Company By Expanding Its Branded And Specialty Products, Unlocking Biotech Potential Through IGI, And Focusing On Sustainable Growth In Key Therapeutic Areas And Regions. 💊🌍

Glenmark Pharma shares in focus after USFDA warning to Indore plant

 14 Jul 2025 09:02 AM

Glenmark Pharmaceuticals disclosed receiving a warning letter from the U.S. FDA for its Indore facility following a February inspection. The company clarified that the letter won’t impact existing supplies or revenues. It also emphasized its commitment to compliance and noted no data integrity issues were found.

Glenmark Pharma: Co. Receives USFDA Warning Letter For Indore Facility, No Data Integrity Issues Found And No Supply Or Revenue Disruptions Expected. 📭🧪

 14 Jul 2025 08:26 AM

Glenmark Pharma: Co. Receives USFDA Warning Letter For Indore Facility, No Data Integrity Issues Found And No Supply Or Revenue Disruptions Expected. 📭🧪

Ahead of Market: 10 things that will decide stock market action on Monday

 13 Jul 2025 03:21 PM

Indian markets closed lower for the second straight week, dragged by weak earnings, US tariff threats, and global uncertainty. IT stocks underperformed while Glenmark Pharma led in turnover. Analysts expect volatility ahead amid weak momentum. Global markets also declined. Over 130 stocks hit 52-week highs despite a broadly bearish sentiment.